Lista de obras - Nicola Giuliani - Dominio Público Uruguay

5-HT3 serotonergic receptor mediation of hypoglycemia-induced arginine-vasopressin but not oxytocin secretion in normal men.

artículo científico publicado en 1998

A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis.

artículo científico publicado en 2018

Angiogenesis and Multiple Myeloma ⬇️

artículo científico publicado el 7 de julio de 2011

Angiogenic switch in multiple myeloma.

artículo científico publicado en 2004

Angiopoietin-1 and myeloma-induced angiogenesis.

artículo científico publicado en 2005

Angiopoietins expression by human myeloma cells

artículo científico publicado en 2003

Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma

artículo científico publicado en 2020

Arginine vasopressin and oxytocin responses to angiotensin II are mediated by AT1 receptor subtype in normal men

artículo científico publicado en 1998

Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation.

artículo científico publicado en 2006

Biology and treatment of multiple myeloma

artículo científico publicado en 2006

Bisphosphonates inhibit IL-6 production by human osteoblast-like cells

artículo científico publicado en 1998

Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo

artículo científico publicado en 1998

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients

scientific article published on 06 March 2019

Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.

artículo científico publicado en 2017

Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma

artículo científico

Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2.

artículo científico publicado en 2014

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients

artículo científico publicado en 2010

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

artículo científico publicado en 2010

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

artículo científico publicado en 2013

Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy

scientific article published on 11 July 2020

CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

artículo científico publicado en 2008

CD14+ CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy

artículo científico publicado en 2020

CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents

scientific article published on 13 December 2019

CD38 and bone marrow microenvironment.

artículo científico publicado en 2014

Clinical observations with a new specific assay for bone alkaline phosphatase: a cross-sectional study in osteoporotic and pagetic subjects and a longitudinal evaluation of the response to ovariectomy, estrogens, and bisphosphonates

artículo científico publicado en 1996

Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients

scientific article published on 06 January 2020

Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.

artículo científico publicado en 2008

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

artículo científico publicado en 2016

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.

artículo científico publicado en 2016

Different effects of naloxone on the growth hormone response to melatonin and pyridostigmine in normal men

scientific article published on 01 July 1998

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

artículo científico publicado en 2009

Do human myeloma cells directly produce basic FGF?

artículo científico publicado en 2003

Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?

artículo científico publicado en 2004

Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis.

artículo científico publicado en 2004

Effect of melatonin on arginine vasopressin secretion stimulated by physical exercise or angiotensin II in normal men.

artículo científico publicado en 1998

Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycaemia in insulin-dependent diabetics.

artículo científico publicado en 1998

Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma

artículo científico publicado en 2007

Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma

artículo científico publicado en 2020

Functional Consequences of Low Activity of Transport System A for Neutral Amino Acids in Human Bone Marrow Mesenchymal Stem Cells

scientific article published on 10 March 2020

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo

artículo científico publicado en 2016

Gene array profile identifies collagen type XV as a novel human osteoblast-secreted matrix protein

artículo científico publicado en 2009

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

artículo científico publicado en 2010

Hematologic Malignancies With Extramedullary Spread of Disease

artículo científico publicado en 2003

Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients

artículo científico publicado en 2005

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

artículo científico publicado en 2002

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

artículo científico publicado en 2013

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules

artículo científico publicado en 2012

Impact of XIAP protein levels on the survival of myeloma cells

artículo científico publicado en 2008

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.

artículo científico publicado en 2012

Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease

artículo científico publicado en 1996

Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array

artículo científico publicado en 2011

Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma.

artículo científico publicado en 2010

Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients

artículo científico publicado en 2006

Lack of increased serum interleukin-6 and soluble IL-6 receptor concentrations in patients with thyroid diseases following recombinant human interferon alpha therapy

artículo científico publicado en 1996

Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells

artículo científico publicado en 2005

Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts

article

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells

artículo científico publicado en 2010

MDR1 polymorphism influences the outcome of multiple myeloma patients.

artículo científico publicado en 2007

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling

artículo científico publicado en 2015

Melatonin inhibits oxytocin response to insulin-induced hypoglycemia, but not to angiotensin II in normal men.

artículo científico publicado en 1998

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

artículo científico publicado en 2007

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma

scientific article published on 19 September 2020

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

artículo científico publicado en 2006

Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability

artículo científico publicado en 2020

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

artículo científico publicado en 2005

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

artículo científico publicado en 2001

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.

artículo científico publicado en 2012

NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model

artículo científico publicado en 2015

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

artículo científico publicado en 2004

New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics

artículo científico publicado en 2013

Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies

artículo científico publicado en 2020

Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells ⬇️

artículo científico publicado el 31 de agosto de 2011

Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.

artículo científico publicado en 2013

Novel targets for the treatment of relapsing multiple myeloma

artículo científico publicado en 2019

OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?

artículo científico publicado en 2004

Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.

artículo científico publicado en 2009

Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

artículo científico publicado en 2015

Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations

article

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression

artículo científico publicado en 2021

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

artículo científico publicado en 2013

Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis

artículo científico publicado en 2003

Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.

artículo científico publicado en 2007

Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms

artículo científico publicado en 2007

Role of Galectins in Multiple Myeloma

artículo científico publicado en 2017

Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking

scientific article published on 01 August 2000

Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes

artículo científico publicado en 2001

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

artículo científico publicado en 2022

Stimulation of ACTH and GH release by angiotensin II in normal men is mediated by the AT1 receptor subtype

artículo científico publicado en 1998

Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.

artículo científico publicado en 2008

Targeting pathways mediating bone disease

artículo científico publicado en 2006

Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome

artículo científico publicado en 2015

The Circular Life of Human CD38: From Basic Science to Clinics and Back

artículo científico publicado en 2020

The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors

artículo científico publicado en 2015

The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2004

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

artículo científico publicado en 2015

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angio

artículo científico publicado en 2007

The osteoblastic niche in the context of multiple myeloma

artículo científico publicado en 2014

The possible role of hematin and Mössbauer effect in the inhibition of osteosarcoma cell proliferation

artículo científico publicado en 1998

The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

artículo científico publicado en 2010

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

artículo científico publicado en 2007

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

artículo científico publicado en 2009

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.

artículo científico publicado en 2016

Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche.

artículo científico publicado en 2014

e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?

artículo científico publicado en 2004

Lista de obras de Nicola Giuliani

5-HT3 serotonergic receptor mediation of hypoglycemia-induced arginine-vasopressin but not oxytocin secretion in normal men.

A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis.

Angiogenesis and Multiple Myeloma ⬇️

Angiogenic switch in multiple myeloma.

Angiopoietin-1 and myeloma-induced angiogenesis.

Angiopoietins expression by human myeloma cells

Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma

Arginine vasopressin and oxytocin responses to angiotensin II are mediated by AT1 receptor subtype in normal men

Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation.

Biology and treatment of multiple myeloma

Bisphosphonates inhibit IL-6 production by human osteoblast-like cells

Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients

Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.

Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma

Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2.

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy

CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

CD14+ CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy

CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents

CD38 and bone marrow microenvironment.

Clinical observations with a new specific assay for bone alkaline phosphatase: a cross-sectional study in osteoporotic and pagetic subjects and a longitudinal evaluation of the response to ovariectomy, estrogens, and bisphosphonates

Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients

Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.

Different effects of naloxone on the growth hormone response to melatonin and pyridostigmine in normal men

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

Do human myeloma cells directly produce basic FGF?

Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?

Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis.

Effect of melatonin on arginine vasopressin secretion stimulated by physical exercise or angiotensin II in normal men.

Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycaemia in insulin-dependent diabetics.

Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma

Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma

Functional Consequences of Low Activity of Transport System A for Neutral Amino Acids in Human Bone Marrow Mesenchymal Stem Cells

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo

Gene array profile identifies collagen type XV as a novel human osteoblast-secreted matrix protein

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

Hematologic Malignancies With Extramedullary Spread of Disease

Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules

Impact of XIAP protein levels on the survival of myeloma cells

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.

Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease

Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array

Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma.

Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients

Lack of increased serum interleukin-6 and soluble IL-6 receptor concentrations in patients with thyroid diseases following recombinant human interferon alpha therapy

Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells

Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells

MDR1 polymorphism influences the outcome of multiple myeloma patients.

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling

Melatonin inhibits oxytocin response to insulin-induced hypoglycemia, but not to angiotensin II in normal men.

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.

NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics

Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies

Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells ⬇️

Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.

Novel targets for the treatment of relapsing multiple myeloma

OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?

Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.

Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression